用于多囊卵巢综合征诊断的细胞外囊泡蛋白标志物及应用
By screening extracellular vesicle protein markers such as FCN1 and HLA-B27, a kit was prepared for the diagnosis of PCOS, which solved the problems of complexity and inconsistency in existing diagnostic methods and achieved a highly accurate and convenient diagnosis.
CN122410018APending Publication Date: 2026-07-17JIANGSU PROVINCIAL HOSPITAL OF TCM
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- JIANGSU PROVINCIAL HOSPITAL OF TCM
- Filing Date
- 2026-04-20
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing diagnostic methods for polycystic ovary syndrome (PCOS) are complex, easily confused with other endocrine disorders, and lack specific serological molecular markers, resulting in inconsistent diagnostic criteria.
Method used
Extracellular vesicle protein markers such as FCN1 and HLA-B27 were screened and used to prepare a kit for the diagnosis of PCOS. Receiver operating characteristic (ROC) curve analysis was combined to improve diagnostic accuracy.
Benefits of technology
It provides specific and sensitive diagnostic methods for PCOS, simplifies the diagnostic process, improves diagnostic accuracy and efficiency, and reduces patient suffering.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122410018A_ABST
Abstract
本发明属于生物医学技术领域，具体而言，涉及一种用于多囊卵巢综合征诊断的细胞外囊泡蛋白标志物及应用。所述细胞外囊泡蛋白标志物包括FCN1、HLA‑B27中的一种或两种的组合。本发明首次将FCN1等多种细胞外囊泡蛋白用于多囊卵巢综合征患者的诊断中，经在本发明收集的真实临床样本中进行验证发现，所述FCN1等多种细胞外囊泡（EVs）蛋白对多囊卵巢综合征的诊断具有较好的诊断效能，准确性、敏感性和特异性均较高，能够用于多囊卵巢综合征的有效诊断。本发明为多囊卵巢综合征相关诊断产品的研究和开发提供了全新的思路和策略，在多囊卵巢综合征诊断这一技术领域具有广泛的应用前景和重要的转化意义。
Need to check novelty before this filing date? Find Prior Art